Nautic invests in specialty pharmacy SenderraRx

The deal is expected to close in the first quarter of 2026.

  • SenderraRx’s management team will remain significant investors and continue to lead the company
  • SenderraRx specializes in treating patients with complex and chronic conditions such as dermatology, rheumatology and oncology
  • Will Howard serves as CEO and co-founder of SenderraRx

Nautic Partners has agreed to make a growth investment in SenderraRx, a Dallas-based specialty pharmacy.

Share this